A digital smoking cessation program delivered through internet and cell phone without nicotine replacement (happy ending): randomized controlled trial.

Plain-language guide to PMID 19087949 (2008): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 19087949
Journal: Journal of medical Internet research
Year: 2008
Study type: Randomized Controlled Trial
Authors: Brendryen H et al. (3 authors)
DOI: 10.2196/jmir.1005

What This Study Did, in Plain Language

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Happy Ending (HE) is an intense 1-year smoking cessation program delivered via the Internet and cell phone.

HE consists of more than 400 contacts by email, Web pages, interactive voice response, and short message service technology.

Who Took Part

By PubMed's age tags, the people studied were teenagers and young adults.

Subjects were recruited via Internet advertisements and randomly assigned to condition.

Inclusion criteria were willingness to quit on a prescribed day without using nicotine replacement and being aged 18 years or older.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

A two-arm randomized controlled trial was used.

The intervention group received HE, and the control group received a 44-page self-help booklet.

Abstinence was defined as "not even a puff of smoke, for the last seven days" and was assessed by means of Internet surveys or telephone interviews 1, 3, 6, and 12 months postcessation.

The main outcome was repeated point abstinence (ie, abstinence at all four time points).

What Was Measured

PubMed files the paper under topics including Behavior Therapy, Cell Phone, Electronic Mail, Happiness, Internet, Multimedia and Nicotine.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Journal of medical Internet research), a journal based in Canada.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.